Clinical Trial

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

Study acronym: TROJAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2023 (before its estimated July 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-12-16; most recent amendment 2023-09-19.
Status change: Not Yet Recruiting → Recruiting 2020-01-07
Trial Details
NCT Number NCT03379909
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Radboud University Medical Center
Conditions Superficial Bladder Cancer, Bladder Cancer
Enrollment 49 participants
Start Date 2019-09-01
Primary Completion 2024-07-31 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2023-09-21